Kiosk Store makes interactive maps user friendly Aug 8, 2008
Jim Poulin/Phoenix Business Journal The Kiosk Store Chief Technology Officer Justin Crowford, left, and founder and CEO Craig Pozen show off the company. Craig Pozen got tired of not knowing where he was going, so he developed a method to find his way ... Pozen founded , a Scottsdale-based business that develops software for electronic kiosks used in public places ranging from malls to hospitals. (Phoenix Business Journal, AZ)
POZEN Receives Initial FDA Response To PA32540 SPA Aug 3, 2008
CHAPEL HILL, N.C., Aug 01, 2008 (BUSINESS WIRE) ----POZEN Inc. (NASDAQ: POZN), today announced that the U.S. Food and Drug Administration (FDA) has provided an initial response to POZEN's Special Protocol Assessment (SPA) for PA32540, which was submitted in June 2008 ... POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience ... POZEN's efforts are focused primarily... (FOXBusiness)
GlaxoSmithKline payment boosts Pozen earnings Jul 29, 2008
Pozen (Nasdaq: POZN) reported net income of $13 ... Pozen s second quarter 2008 results matched Wall Street s prediction for profit and beat the Street on revenue ... Analysts polled by were projecting, on average, that Pozen would post net income of 43 cents per diluted share on $29. (Raleigh Triangle Business Journal, NC)
Laws not crowding area jails Jul 21, 2008
" Clarke sheriff's officials looked into the program, but decided not to participate. "It would require our employees to conduct the entire status investigation for ICE," Pozen said. "We determined the best use of our personnel was to run a query. then notify ICE as described in our policy and procedures. (Athens Banner-Herald)
Virtual biotech: Real money, real questions Jul 16, 2008
Even after the approval earlier this year of the company's first drug, migraine treatment Treximet, Pozen has only 30 to 40 full-time workers at any given time ... Pozen, for example, employs workers who focus on the management and interpretation of clinical data. (Raleigh Triangle Business Journal, NC)
New SEC disclosure rules could help investors by letting in more sunshine Jun 25, 2008
The group, chaired by Robert Pozen, the former vice chairman of Boston-based Fidelity Investments, has been studying how to reduce the number of restatements, make management discussions of financial results clearer, and simplify accounting. Karey Wutkowski is a Reuters reporter. (Boston Globe)
Putnam taps former Fidelity executive as CEO Jun 13, 2008
Other former Fidelity executives have risen to great heights under Johnson before joining other firms - notably Robert Pozen, once Fidelity's investment chief, who in 2004 joined MFS Investment Management as its nonexecutive chairman. But as a former Fidelity star now quarterbacking an opposing team, Reynolds may pose the sharpest chal lenge for Fidelity even though it dwarfs Putnam in size, with assets under management of $1. (Boston Globe)
He's the man - if fund firm is able to improve performance Jun 13, 2008
Bob Pozen, a lawyer, took that walk before him and eventually joined another Boston firm, MFS Investment Management, as its high-impact chairman. But MFS was facing serious legal and regulatory problems at the time, so it was clear how he might be the right person at the right time. (Boston Globe)
Mental health: Broken system, shattered lives Jun 8, 2008
About twice as many prisoners at the local jail, or 30 percent, have been diagnosed with mental illness, Clarke County sheriff's Capt. Eric Pozen said. Mentally ill people all across Georgia are warehoused in jails, most of which do not have psychiatric units, according to Brett Hart, former commander of the Clarke County Jail. (Athens Banner-Herald)
Trials costs inflate Pozen's loss May 8, 2008
Losses widened for drug maker Pozen in the first quarter as it ratcheted up work on trials of a late-stage drug. Chapel Hill-based Pozen (Nasdaq: POZN), which to sell its migraine drug, Treximet, said it lost $7 ... The wider losses came from an increase in operating expenses related to late-stage human trials of PN 400, an arthritis drug Pozen is co-developing with AstraZeneca. (Triangle Business Journal)
Grand jury, A-C commissioner push hard for new Clarke jail May 6, 2008
" Mold and mildew, which can lead to respiratory problems, grows everywhere in the jail from moisture thrown off by so many bodies, as well as from showers and from water leaking in from outside, Burke said. MULTIMEDIA PDF: View a copy of the grand jury's report: (144k) Toilets sometimes back up because the plumbing system is overtaxed, he said, but mostly it's because inmates clog them intentionally. The 330-bed jail was built in 1981, a time when the building held an average of 100-150... (Athens Banner-Herald)
GlaxoSmithKline May 2, 2008
The payment to Chapel Hill-based Pozen (Nasdaq: POZN) was triggered by the April 15 approval of the treatment by the U.S. Food and Drug Administration. Pozen co-developed Treximet with Glaxo (NYSE: GSK) and will receive royalties on sales of the drug ... Pozen said Monday that it's still on track to get Treximet into pharmacies by mid-May. (Raleigh Triangle Business Journal, NC)
Pozen-GSK migraine drug wins FDA approval Apr 22, 2008
Pozen has won approval from the U.S. Food and Drug Administration for the Treximet migraine drug it developed with , the company said late Tuesday. The announcement brings vindication to Chapel Hill-based Pozen (NASDAQ:POZN), which is co-developing Treximet along with GlaxoSmithKline (NYSE:GSK) ... Chapel Hill, N.C.-based Pozen and GSK expect to launch Treximet in mid-May. (Philadelphia Business Journal, PA)
FDA approves Pozen drug; stock jumps Apr 17, 2008
The decision, announced Tuesday night, brought vindication to Chapel Hill-based Pozen (Nasdaq: POZN), which is co-developing Treximet along with (NYSE: GSK) ... Pozen and GSK expect to launch Treximet in mid-May ... It will be the first drug on the market for Pozen, whose stock price was up more than 30 percent, to $13. (Raleigh Triangle Business Journal, NC)
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine Apr 16, 2008
Clinical studies show Treximet provided significantly more patients migraine pain relief compared to sumatriptan 85 mg LONDON, April 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE: GSK) (NYSE: ) and POZEN Inc. (Nasdaq: ) announced today that the FDA has approved Treximet for the acute treatment of migraine attacks with or without aura in adults ... About POZEN (Nasdaq: ) POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs... (PR Newswire)
Audit Brothel's Grand Re-Opening May Come Soon Mar 28, 2008
What the Pozen committee has floated, in a 111-page report released Feb. 14, would turn the prevailing definition of materiality on its head ... Pozen and his cohorts should stick to their day jobs. (Bloomberg -- Columnists)
Professorship endowed in Human Rights Program Mar 21, 2008
The College will bring a senior-level scholar in human rights to campus through the Pozen Visiting Professorship in Human Rights, which has been newly endowed with a $1 million gift from Richard Pozen (A.B. 69) and his wife, Ann Silver Pozen ... We are extremely grateful to Richard and Ann Pozen for investing in the future of our Human Rights program and in the educational accomplishments of the College more generally, Boyer said ... The Pozen Visiting Professorship will enable us to bring many... (Univeristy of Chicago Chronicle, IL)
Pozen gives raise to CEO Plachetka Mar 15, 2008
Pozen (Nasdaq: POZN) is developing a migraine drug called Treximet with (NYSE: GSK). Rollout of the drug twice has been delayed by the U.S. Food and Drug Administration, which sought more safety information on the treatment, but the companies hope to win FDA approval for Treximet this year. (Raleigh Triangle Business Journal, NC)
Taking the mess out of fingerprinting Mar 6, 2008
" Athens-Clarke police used a grant a couple of years ago to get another live-scan machine for the jail and took the older one to police headquarters, he said. Law-abiding citizens also need fingerprints for lots of reasons, from getting a liquor license or gun permit, to working in child care or real estate. Until recently, locals could go to police headquarters on Lexington Road for an inkless fingerprint, or go to the courthouse, where they would walk away with black fingertips. That changed... (Athens Banner-Herald)
AstraZeneca, GSK help Pozen post profit Feb 27, 2008
2 million in revenue from AstraZeneca and GSK for development work pushed Pozen (Nasdaq: POZN) to a 2007 profit of $4 ... Analysts polled by Thomson Financial had projected 2007 earnings of 12 cents per diluted share for Pozen ... Pozen also beat the Thomson Financial analysts' earnings projection for the fourth quarter of 2007. (Raleigh Triangle Business Journal, NC)
Amid cheers, officer offto rehab center in Atlanta Jan 26, 2008
" People started to gather in the hospital about 8 a.m. Friday. By the time Gale appeared nearly two hours later, the lobby was filled with officers from the Athens-Clarke and University of Georgia police departments, the Clarke and Oconee county sheriff's offices, the Georgia Bureau of Investigation and the district attorney's office. Clarke County sheriff's Capt. Eric Pozen brought Gale two armfuls of flowers, and county Human Resources Director Harry Owens placed a "Good Luck" placard on her... (Athens Banner-Herald)
Pozen shares rise on migraine drug test Jan 16, 2008
Chapel Hill-based Pozen (Nasdaq: POZN) had the tests done to help alleviate U.S. regulators' concerns about the drug's genotoxicity, or its potential to cause harmful mutations that can lead to diseases including cancer. On Tuesday, Pozen said a short-term study of human volunteers shows that the drug, formerly known as Trexima and tentatively known now as Treximet, did not cause any harmful mutations in white blood cells when given to patients over the course of one week. (Raleigh Triangle Business Journal, NC)
GEORGIA BLUE CHIPS Jan 12, 2008
Any move away from industry-specific accounting would be a big change likely to touch off considerable controversy, according to MFS Investment Management Co. Chairman Robert Pozen, who heads the SEC advisory panel on improvements to financial reporting. ajc. (Atlanta Journal-Constitution -- Business)
Blogging under 21 Jan 3, 2008
He also notes that "their shows are always all ages, and are usually five bucks to enter." Pitchfork-feted "indy-dance pop-culture kingpin of our generation" Dan Deacon is scheduled to play the Pozen Center on Jan. 31. Pozen Center, Mass Art, 621 Huntington Ave., Boston. (Boston Globe)
Why You Need a Personal Health Record Dec 16, 2007
"Many people think that if they're healthy they don't need a personal health record," says Denise Pozen, attorney and creator of So Tell Me ... "But a PHR can be beneficial to almost everyone, regardless of their health.Pozen goes on to explain that a PHR is more than just a compliation of your medical records. "It is an ongoing personalized compilation of important personal and health related information about you or someone you're caring for that you can have on hand any time you visit a new... (Atlantic News-Telegraph, IO)
Late TV listings Nov 25, 2007
Guests: Robert Pozen, chairman of MFS Investments; Chip Bergh, president of Global Grooming, Procter & Gamble; Larry Bacow, president of Tufts University; and Henri Termeer, CEO of Genzyme. 12:30 p.m. (NECN). (Boston Globe)
Raid corporate pirates' arsenal Nov 11, 2007
So says Robert C. Pozen, chairman of the Boston money management firm MFS Investment Management ... "Directors of public companies would do well to step back and look with cool eyes at how the top private equity firms have produced such high returns," Pozen wrote ... But businesses intent on staying independent, controlling their destinies, and reaping the benefits of their growth should understand and use private equity techniques, Pozen said. (Boston Globe -- Business)
Pozen swings to profit on AstraZeneca payment Nov 2, 2007
Nearly all of the company's revenue came from a September payment from AstraZeneca, which is developing an arthritis painkiller called PN 400 with Pozen ... That triggered a $30 million milestone payment to Pozen with the promise of another $315 million on the horizon ... Pozen, which has no drugs on the market and no sales force, relies on its partnerships for revenue. (Raleigh Triangle Business Journal, NC)
As jail swells, so does the bill Oct 28, 2007
" "A lot of offenses, you can release people on citations," said Capt. Eric Pozen, a spokesman for Edwards. "They don't have to be arrested ... try to manage the population proactively, maybe we won't need as much money as the sheriff is asking for," Reddish said. The vast majority of inmates - 72 percent - are either awaiting bond or a hearing. Reddish said he wants the sheriff to update courts daily on which inmates can be released. And Edwards says he's working with judges to speed up... (Athens Banner-Herald)
Pozen shares drop on downgrade Oct 17, 2007
The announcement came a day after Pozen said it would be to determine whether high doses of Trexima are harmful to humans. Pozen also submitted preclinical data to the FDA that is meant to alleviate those concerns ... It would a setback for Pozen, which wants to get to give it a step up on expected generic competition. (Raleigh Triangle Business Journal, NC)
Pozen to test toxicity of migraine drug Oct 16, 2007
The study, to be done in humans, comes on top of preclinical data Pozen recently submitted to the Food and Drug Administration ... But Pozen said regulators also might want safety data from human studies ... "Although we believe that our submission addresses FDA's concern regarding the genotoxic potential of Trexima, we feel it is prudent to conduct this clinical trial so that we can provide this information without delay, if required," Marshall Reese, Pozen's executive vice president for... (Raleigh Triangle Business Journal, NC)
Pozen sends safety data to FDA; shares rise Oct 7, 2007
The information is a response to the FDA's early August request to get more safety information on the drug, which Chapel Hill-based Pozen is developing along with. That request, the FDA's second delay in approving Trexima, sent shares of Pozen (NASDAQ: POZN) down 45 percent ... At the time, analysts said Pozen and GSK needed to to get the additional safety data to the FDA so Trexima could get a head start on any generic competition. (Raleigh Triangle Business Journal, NC)
Jail for author of a perfect crime Sep 8, 2007
Share your travel experiences and win a trip to Milan. Navigation - link to other main sections from here. (Times Online)
Pozen posts big gains as painkiller gets earlier testing Sep 8, 2007
Sabine Vollmer, Staff Writer After its experimental migraine treatment fell short of regulatory approval a second time last month, Pozen needed some good news ... Pozen has been working on the painkiller -- called PN 400 -- with British partner AstraZeneca for about a year ... Advancing the drug to tests involving about 800 patients triggers a $30 million payment from AstraZeneca and puts Pozen closer to another $315 million for developmental, regulatory and sales milestones. (News & Observer)
Pozen gets boost from phase III start, amended AstraZeneca deal Sep 7, 2007
The deal calls for Pozen to get a $30 million payment up front from AstraZeneca, up from the $20 million it had previously expected at the start of phase III trials of the drug, known as PN 400 ... Pozen is eligible to receive $85 million in development and regulatory milestones under the new deal, down from $160 million under the original agreement ... PN 400 uses Pozen's proprietary drug-combination technology to fuse AstraZeneca's heartburn treatment Nexium with the anti-inflammatory drug... (Raleigh Triangle Business Journal, NC)
Back to School with a "Healthful" Tool Aug 25, 2007
"Keeping organized is a key component to starting the school year smoothly. to manage and track your child's health information will streamline one of your many tasks as a parent. Including a PHR with your college student's dorm room accessories will add peace of mind," says Denise Pozen, attorney and creator of the The So Tell Me brand ... For more information on organizing personal health records contact Pozen Services Inc. at. (Sebastopol Sonoma West Publishing, CA)
Get a Deep Insight into The CNS (Central Nervous System) Therapeutics Market Aug 23, 2007
Business Wire: public relations, press release distribution, investor relations, SEC filing. August 23, 2007 04:00 AM Eastern Daylight Time. (BusinessWire)
FDA Rejects A Slew Of Experimental Drugs Aug 18, 2007
One, Pozen Inc., this month got its second FDA request for more information about a migraine treatment called Trexima it is jointly developing with GlaxoSmithKline. That news sent Pozen shares down 46 percent. (CBS New York, NY)
Glaxo, Wyeth, Sanofi Revival Thwarted by U.S. Regulator's Drug Rejections Aug 16, 2007
The agency on Aug. 2 requested more data on Trexima, a migraine pill developed by Glaxo and Pozen Inc. On Aug. 10, the FDA withheld approval of a longer-acting version of Glaxo's Requip restless leg syndrome medicine, and asked how the company will distinguish the new version from the original in the prescribing information. Sanofi's diet pill, sold in Europe as Acomplia, is the French company's most important new medicine, and lack of U.S. approval means it won't reach a goal for $3 billion a... (Bloomberg -- Europe)
Federman & Sherwood Announces That a Securities Class Action Lawsuit has Been Filed Against Pozen Inc. Aug 14, 2007
Federman ood Announces That a Securities Class Action Lawsuit has Been Filed Against Pozen Inc. ... Federman ood Announces That a Securities Class Action Lawsuit has Been Filed Against Pozen Inc. ... OKLAHOMA CITY, Aug. 13 /PRNewswire/ -- On August 10, 2007, a class action lawsuit was filed in the United States District Court for the Middle District of North Carolina against POZEN Inc. (Nasdaq: ). (PR Newswire)
Plachetka's take in Pozen stock sales at $3.6M in '07 Aug 13, 2007
Plachetka's take in Pozen stock sales at $3 ... Plachetka's take in Pozen stock sales at $3 ... CHAPEL HILL - While investors were lapping up Pozen's shares amid company optimism and media hype that a promising migraine drug was headed toward regulatory approval, Pozen's chief executive and a director were cashing out through automated stock-selling programs. (Raleigh Triangle Business Journal, NC)
Schatz Nobel Izard P.C. Announces Class Action Lawsuit Against POZEN, Inc. Aug 11, 2007
Aug. 10, 2007 (PRIME NEWSWIRE) -- The law firm of Schatz Nobel Izard P.C., which has significant experience representing investors in prosecuting claims of securities fraud, announces that a lawsuit seeking class action status has been filed in the United States District Court for the Middle District of North Carolina on behalf of all persons who purchased the publicly traded securities of POZEN, Inc. (``POZEN'') (NasdaqGM: - ) between July 31, 2006 and August 1, 2007, inclusive (the ``Class... (Primezone Releases)
Dangerous job claims one more Aug 8, 2007
An all-star lineup of top executives -- Sam Bodman, Jack O'Brien, Bob Pozen, Bob Reynolds, and now Ellyn McColgan -- have come and gone because their name was not Johnson. Rodger Lawson, 60, is no more likely to run Fidelity, either. (Boston Globe)
Delay for drug costly to Pozen Aug 8, 2007
Sabine Vollmer, Staff Writer The Food and Drug Administration's decision to delay approval of Pozen's migraine pill Trexima could cost employees at the Chapel Hill drug company more than $2 million ... Pozen's board of directors has "clearly tied compensation to approval," said Ken Trbovich, a pharmaceutical analyst with RBC Capital Markets ... Trexima is Pozen's third attempt to get a drug to market. (News & Observer)
Pozen shares plunge; clock ticking on drug Aug 4, 2007
The problem is bigger than the 45 percent drop in Pozen's share price Thursday. The Food and Drug Administration's request means that Pozen, which developed Trexima with GlaxoSmithKline, most likely will need to run additional tests on the drug ... Asked about the issue in a conference call with analysts, Pozen CEO John Plachetka acknowledged the urgency. (Raleigh Triangle Business Journal, NC)
Pozen Shares Plunge on Delay to Trexima Migraine Drug (Update2) Aug 3, 2007
Pozen Shares Plunge on Delay of Trexima Migraine Drug (Update3) ... Aug. 2 (Bloomberg) -- Shares of Pozen Inc., the biotechnology company developing the migraine pill Trexima, fell the most in more than a year after U.S. regulators delayed approving the medicine a second time for safety reasons ... The Food and Drug Administration asked Pozen and partner GlaxoSmithKline Plc, the world's second-largest pharmaceuticals company, for more information on a laboratory study that linked the product... (Bloomberg)
Drug groups face review of NHS price contract Aug 3, 2007
Shares in Pozen Pharmaceuticals, GlaxoSmithKline s US development partner on Trexima, a new combination migraine medicine, plunged by 45 per cent yesterday after the US Food and Drug Administration refused for a second time to approve the drug (Robin Pagnamenta writes). Glaxo, Britain s largest pharmaceutical company, said that the FDA has requested further information about Trexima, amid concern that it could damage patients DNA. The pill, made from the painkiller naproxen sodium combined with... (Times Online)
Abrupt end at Evergreen Aug 2, 2007
Good luck, Bob Pozen ... Pozen, the chairman of MFS Investment Management, is also chairman of the SEC's committee. (Boston Globe)
Pozen shares up as FDA decision nears Aug 2, 2007
The is expected to say today whether it will approve Trexima, which Pozen developed in correlation with ... Shares of Pozen (Nasdaq: POZN) were up $1. (Raleigh Triangle Business Journal, NC)
Pozen hires chief medical officer Jul 28, 2007
He will be in charge of overseeing the safety and monitoring of Pozen's clinical trials. The announcement comes as Pozen awaits word from the on approval for its migraine drug Trexima. (Triangle Business Journal)
Three Stocks to quadruple in price in next 12 months Jul 26, 2007
Three stocks to quadruple in price in the next 12 months from my list of 53 small company stocks that already gained an average of 408% in 2006/2007. When you see gains like 1,339. (Newsmax)
A New Tool to Address the Needs of Our Aging Population Jul 21, 2007
Denise Pozen of LaGrange, Ill ... "I started going through the exact same experience again, so one day I decided to just write down the answers to all the common questions I was being asked and organize them in a binder, along with photocopies of test results, prescriptions and other medical information I had gathered," says Pozen ... Pozen says the doctors and nurses she encountered were so impressed by what she had done, she decided to start marketing her idea. (Atlantic News-Telegraph, IO)
Romney took on 'outsider' role at helm of Bay State Jul 6, 2007
His Cabinet choices seemed to reflect a new approach, creating a "wow" effect with high-powered members such as Democrats Robert C. Pozen, former vice chairman of Fidelity Investments, and Douglas I. Foy, longtime president of the Conservation Law Foundation. They were the biggest names in a strong lineup and Romney gave both broad authority over new "super-secretariats.". (Deseret News)
Guru Picks: Buy Into Small-Caps And AT&T Jul 2, 2007
Two of those small-caps were drug makers Aspreva Pharmaceuticals (nasdaq: - - ) and Pozen (nasdaq: - - ) ... Pozen is another story ... While Aspreva has lost 30% in the past 52 weeks, Chapel Hill, N.C.-based pain medicine maker Pozen has gained 153. (Forbes)
CombinatoRx matches old generic drugs for powerful new medications Jul 1, 2007
For example, Pozen, based in Chapel Hill, North Carolina, is developing combination drugs in partnerships with the pharmaceutical giants GlaxoSmithKline and AstraZeneca. Orexigen Therapeutics of San Diego, recently went public based on the prospects for two combination drugs it is developing to treat obesity. (International Herald Tribune -- Business)
A miracle cure for ailing drug pipelines? Jun 30, 2007
Others in the hunt include Pozen, a company based in Chapel Hill, North Carolina, developing combination drugs in partnerships with the pharmaceutical giants GlaxoSmithKline and AstraZeneca. Today in Business. (International Herald Tribune -- Money Report)
Pozen senior VP steps down Jun 12, 2007
She has been with Pozen since 1999 ... The resignation comes as Pozen seeks regulatory approval for its lead drug candidate, the , which some analysts have labeled a potential blockbuster. (Triangle Business Journal)
Kristina Adomonis Jun 12, 2007
Pozen senior VP steps down - Triangle Business Journal ... Pozen senior VP steps down ... She has been with Pozen since 1999. (Triangle Business Journal)
Chairman sees no benefit to selling MFS May 23, 2007
MFS Investment Management, the Boston mutual fund company that was put up for sale and then taken off the market last year, would gain no advantages from being sold, according to its chairman, Robert Pozen. " /> Chairman sees no benefit to selling MFS Bloomberg News Published: May 23, 2007 Text Size MFS Investment Management, the Boston mutual fund company that was put up for sale and then taken off the market last year, would gain no advantages from being sold, according to its chairman, Robert... (International Herald Tribune -- Business Asia)
Bernanke's False Dichotomy May 19, 2007
By Robert C. Pozen Word Count: 845. Responding to the declining U.S. role in global capital markets, Federal Reserve Chairman Ben Bernanke called Tuesday for moving away from the detailed rules of U.S. financial regulation toward the "principles-based, risk-based" system of the Financial Services Authority (FSA) in the United Kingdom. (Wall Street Journal)
Giving Up on Giving Guidance May 16, 2007
"Issuing [quarterly] guidance is a fool's game," says Robert Pozen, chairman of MFS Investment Management in Boston and member of a U.S. Chamber of Commerce group that recently examined the issue ... Pozen and other members of a commission assembled by the U.S. Chamber of Commerce recently put out a study that argues the U.S. is in danger of losing its leadership in capital markets, in part because of guidance ... If they succeed, Pozen says, he hopes "markets believe this is a larger positive... (MSNBC -- Business)
How to strengthen Wall Streets global share Apr 26, 2007
FT.com / Comment & analysis / Comment - How to strengthen Wall Streets global share. Financial Times FT.com. (FT.com -- Markets)
Help Your Favorite Graduate Get Life Started on the Right Foot Apr 25, 2007
is the brainchild of Denise Pozen, who came up with the idea while caring for her sick parents. "When I'd take my mom and dad to various doctors, it seemed they always had the same questions. Did she have a history of fainting spells? What medications was he on? What were the most recent test results at the neurologist's? To keep track of everything, I started jotting down notes in a book I'd bring to all their appointments or send with my sister when she brought them," says Pozen. (Kansas City Kansan, KS)
Climbing Fidelity's ladder? Wear a helmet Apr 20, 2007
Sam Bodman, Jack O Brien, and Bob Pozen, to name three, were among some of Boston s best and brightest who bailed out when they hit the glass ceiling at Fidelity, where the top spot is reserved for those whose name is Johnson. Yesterday, Bob Reynolds, Johnson s latest number two, also chose a similar career path that is, somewhere besides Fidelity. (Boston Globe -- Business)
A surprise retirement changes succession picture at Fidelity Apr 20, 2007
Longtime Fidelity executive Robert Pozen, once in charge of the company s investing arm, decided to leave five years ago. Pozen is now chairman of the financial services firm MFS Investment Management in Boston. (Boston Globe -- Business)
